Metsera Stock Price, News & Analysis

Metsera (NASDAQ: B) announced that its board has declared an amended proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer on Nov 4, 2025. The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share (~$10.0 billion) via a two-step structure: an immediate $62.20 per share cash payment plus non-voting preferred stock, followed by a dividend of $62.20, and a contingent value right (CVR) worth up to $24.00 per share upon regulatory and development milestones.

Metsera notified Pfizer, triggering a two-business-day period for Pfizer to propose adjustments under the Pfizer Merger Agreement; Pfizer previously revised its proposal to $60.00 upfront + up to $10.00 CVR.

Metsera (NASDAQ: MTSR) issued a statement on October 31, 2025 responding to litigation filed by Pfizer, saying Metsera disagrees with the allegations and will address them in the Delaware Court of Chancery.

The release notes risks tied to Pfizer's proposed acquisition of Metsera, including litigation costs, potential damages, possible effects on the timing or completion of the transaction, impacts on Metsera stock price, and references an unsolicited proposal from Novo Nordisk. Metsera also confirms that its definitive proxy statement has been mailed to stockholders and directs investors to SEC filings for more information.

Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).

The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.

Metsera (NASDAQ: B) announced its board has declared an unsolicited proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal would pay $56.50 per share in cash at signing, issue Novo non-voting preferred stock representing 50% of Metsera's share capital, then pay a CVR up to $21.25 per share upon milestones, valuing Metsera at up to $77.75 per share (~$9 billion).

The proposal represents an approximate 133% premium to Metsera's close on Sept 19, 2025. Metsera notified Pfizer, triggering a four-business-day period for Pfizer to propose adjustments; Pfizer disputes Metsera's right to deliver the notice. The Pfizer merger agreement remains in effect and Metsera's board reaffirmed its recommendation to approve the Pfizer transaction; no shareholder action is required now.

Metsera (NASDAQ:MTSR) announced positive Phase 2b results for MET-097i, their first-in-class ultra-long acting GLP-1 receptor agonist candidate. The VESPER-1 trial demonstrated impressive placebo-subtracted weight loss of up to 14.1% after 28 weeks, with individual responses reaching 26.5%. The drug showed potentially best-in-class tolerability with minimal side effects in the VESPER-3 trial, including only 13% nausea and 11% vomiting at the highest dose.

The trials involved 239 participants in VESPER-1 and 268 subjects in VESPER-3, with doses ranging from 0.4mg to 1.2mg. Notably, the study achieved high retention rates with only 2.9% discontinuation in VESPER-1. Based on these positive results, Metsera plans to initiate Phase 3 trials in late 2025, positioning MET-097i as a potential monthly dosing option with dual-agonist-like efficacy.

Pfizer (NYSE:PFE) has announced a definitive agreement to acquire Metsera (NASDAQ:MTSR) in a deal valued at $47.50 per share in cash, representing an enterprise value of $4.9 billion. The deal includes a CVR worth up to $22.50 per share tied to clinical and regulatory milestones.

The acquisition brings Pfizer four clinical-stage incretin and amylin programs targeting obesity and cardiometabolic diseases. Key assets include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist in Phase 2, and MET-233i, a monthly amylin analog in Phase 1, along with two oral GLP-1 RA candidates.

The transaction is expected to close in Q4 2025, subject to regulatory approvals and Metsera shareholder approval. This strategic move positions Pfizer in the growing obesity therapeutic area, which is associated with over 200 health conditions.

Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, will present important data from its obesity treatment portfolio at the 61st EASD Annual Meeting in Vienna, Austria (September 15-19, 2025). The company will showcase three key presentations, including a late-breaking presentation on MET-233i, their ultra-long acting amylin analog.

Chief Medical Officer Steve Marso highlighted the potential of their next-generation nutrient-stimulated hormone (NuSH) therapies, both as standalone treatments and in combinations. Key presentations will feature the pharmacokinetics and weight loss results of MET-233i, and preclinical data on combining MET-233i with MET-097i, their ultra-long acting GLP-1 receptor agonist, representing a first-in-category multi-NuSH combination approach to obesity treatment.